ITP Columns

ITP history

Combining Rituximab and Daratumumab May Be Effective for Post-transplant ITP

A recent study published in Authorea suggests that combination therapy of rituximab and daratumumab might be a promising therapeutic option for refractory post-transplant immune-mediated cytopenias (IMCs) including immune thrombocytopenic purpura (ITP). The researchers presented a case study of a 17-year-old boy with adrenoleukodystrophy who underwent a bone marrow transplant from an unrelated donor using a reduced-intensity conditioning regimen. The…

Next post in ITP Columns